Semaglutide: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 177: | Line 177: | ||
== Further development == | == Further development == | ||
Semaglutide targets a single receptor, GLP-1R. There are dual and triple agonists in development that target multiple receptors. Another avenue of development is to further increase the life-time of synthetic agonists, or to make conjugates that target a payload to cell that carry the GLP-1 receptor. One goal is to find agonists with fewer side effects, and another is to find alternative agonists that are better suited for oral uptake <ref>DOI:10.1016/j.lanepe.2024.101098</ref>. | Semaglutide targets a single receptor, GLP-1R. There are dual and triple agonists in development that target multiple receptors. Another avenue of development is to further increase the life-time of synthetic agonists, or to make conjugates that target a payload to cell that carry the GLP-1 receptor. One goal is to find agonists with fewer side effects, and another is to find alternative agonists that are better suited for oral uptake <ref> | ||
Novikoff, Aaron et al. Why are we still in need for novel anti-obesity medications? The Lancet Regional Health – Europe, Volume 47, 101098 | |||
[https://doi.org/10.1016/j.lanepe.2024.101098 DOI:10.1016/j.lanepe.2024.101098]</ref>. | |||
==Student contributors== | ==Student contributors== | ||
